Beclomethasone dipropionate: Absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man

British Journal of Clinical Pharmacology

Volumn 51, Issue 5, 2001, Pages 400-409

  Daley Yates, Peter T ^a   Price, Alison C ^a   Sisson, Jonathan R ^a   Pereira, Adrian ^a   Dallow, Nigel ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Absolute bioavailability; Beclomethasone dipropionate; Beclomethasone 17 monopropionate; Inhaled; Intranasal; Intravenous; Lung deposition; Oral; Pharmacokinetics

Indexed keywords

ACTIVATED CARBON; BECLOMETASONE; BECLOMETASONE 17 MONOPROPIONATE; BECLOMETASONE DIPROPIONATE; CARBON; DRUG METABOLITE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; INTESTINE; LIQUID CHROMATOGRAPHY; LUNG; MALE; NORMAL HUMAN; NOSE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ADMINISTRATION, INHALATION; ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ADULT; ANTI-ASTHMATIC AGENTS; BECLOMETHASONE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; HUMANS; MALE;

EID: 0034854302     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0306-5251.2001.01374.x     Document Type: Article

References (28)

1. Affinities of glucocorticoids for glucocorticoid receptors in human lung
2. Activation of beclomethasone dipropionate by hydrolysis to beclomethasone-17-monopropionate
3. Biotransformation of topical glucocorticoids, budesonide and beclomethasone 17, 21-dipropionate in human liver and lung homogenate
4. Absorption and metabolism of orally administered beclomethasone dipropionate
5. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety
6. Does swallowing charcoal affect the gastrointestinal absorption of inhaled beclomethasone
7. A method for determination of the absolute pulmonary bioavailability of inhaled drugs: Terbutaline
8. Enantiomeric disposition of inhaled, intravenous and oral racemic-salbutamol in man - No evidence of enantioselective lung metabolism
9. Lung deposition of busesonide from the turbuhaler is twice that from a pressurised metered dose inhaler
10. Beclomethasone dipropionate chlorofluorocarbon and hydrofluoroalkane metered dose inhalers: Relationship between systemic exposure, dose, fine particle mass and particle size in healthy volunteers
11. Plasma levels of beclomethasone dipropionate (BDP) and its metabolite (17-BMP) following BDP inhalation
12. Pharmacokinetics and systemic exposure of inhaled beclomethasone dipropionate
13. Beclomethasone relative availability of oral versus inhaled beclomethasone dipropionate from an HFA-134A metered dose inhaler
14. Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulations
15. Comparison of the clearance of radiolabelled nose drops and nasal spray as mucosally delivered vaccine
16. Pharmacokinetic differences between chlorofluorocarbon and chlorofluorocarbon-free metered dose inhalers of beclomethasone dipropionate in adult asthmatics
17. Enhanced drug delivery through reformulating MDIs with HFA propellants- drug deposition and its effect on preclinical and clinical programs
18. Pharmacokinetics and dose proportionality of beclomethasone from three strengths of a CFC-free beclomethasone dipropionate metered-dose inhaler
19. Beclomethasone dipropionate and budesonide: The clinical evidence reviewed
20. Oral bioavailability of fluticasone propionate in healthy subjects
21. Pharmacokinetics of triamcinolone acetonide after intravenous, oral and inhaled administration
22. The relative systemic exposure to fluticasone propionate and mometasone furoate administered as aqueous nasal sprays in healthy subjects
23. Systemic availability of budesonide after nasal administration of three different formulations; pressurized aerosol, aqueous spray pump and powder
24. Triamcinolone acetonide a review of its pharmacological properties and therapeutic efficacy in the management of allergic rhinitis
25. Systemic effects of two intranasally administered glucocorticoids
26. Pharmacokinetics and bioavailability of intranasal fluticasone in humans
27. Negligible absolute bioavailability and no HPA-axis effects after multiple 200μg daily doses of fluticasone propionate (FP) administered from the aqueous nasal spray (FPANS)
28. Lipophilicity and receptor affinity of glucocorticoids